Profile data is unavailable for this security.
About the company
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases. The Company discovers and develops therapeutics for metabolic dysfunction associated steatohepatitis (MASH) and viruses with high unmet medical need, such as chronic hepatitis B (CHB) and coronaviruses. Its advanced drug candidate for MASH is ALG-055009, a small molecule thyroid hormone receptor beta (THR-ß) agonist. It is also progressing oligonucleotide projects for MASH. It is developing a portfolio of differentiated CHB drug candidates, including a small molecule Capsid Assembly Modulator that results in the production of empty viral capsids (CAM-E) and small molecule inhibitors of the Programmed Cell Death Ligand 1 (PD-1/PD-L1) interaction. Its third area of focus is to develop drug candidates with pan-coronavirus antiviral activity. Its pipeline includes ALG-055009, ALG-000184, ALG-125755, and ALG-097558.
- Revenue in USD (TTM)6.00m
- Net income in USD-76.95m
- Incorporated2018
- Employees68.00
- LocationAligos Therapeutics IncOne Corporate Dr., 2nd Floor, 2nd FloorSOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (302) 658-7581
- Fax+1 (302) 655-5049
- Websitehttps://www.aligos.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CytomX Therapeutics Inc | 126.62m | 13.83m | 69.65m | 120.00 | 5.31 | -- | 4.44 | 0.5501 | 0.1675 | 0.1675 | 1.52 | -0.2998 | 0.7031 | -- | 43.88 | 1,055,142.00 | 7.68 | -21.53 | 29.38 | -32.32 | -- | -- | 10.92 | -100.38 | -- | -- | -- | -- | 90.38 | 11.21 | 99.43 | -- | -26.01 | -- |
| Beyondspring Inc | 1.88m | -15.57m | 70.12m | 35.00 | -- | -- | -- | 37.38 | -0.3987 | -0.3987 | 0.0481 | -0.749 | 0.0698 | -- | -- | 52,111.11 | -59.75 | -75.50 | -102.15 | -96.48 | -- | -- | -856.29 | -4,977.12 | -- | -- | -- | -- | 29.61 | -- | 36.82 | -- | -13.54 | -- |
| Metagenomi Inc | 55.08m | -73.95m | 70.81m | 207.00 | -- | 0.2766 | -- | 1.29 | -2.51 | -2.51 | 1.67 | 6.83 | 0.1479 | -- | 24.41 | 233,389.80 | -19.86 | -- | -23.47 | -- | -- | -- | -134.27 | -- | -- | -- | 0.00 | -- | 160.21 | -- | -56.57 | -- | -- | -- |
| Vistagen Therapeutics Inc | 875.70k | -39.57m | 71.84m | 45.00 | -- | 0.7508 | -- | 82.03 | -1.30 | -1.30 | 0.0289 | 3.44 | 0.0121 | -- | -- | 22,453.85 | -54.69 | -62.84 | -58.94 | -68.03 | -- | -- | -4,518.12 | -5,768.52 | -- | -- | 0.00 | -- | 568.10 | -- | 50.44 | -- | -18.91 | -- |
| Aligos Therapeutics Inc | 6.00m | -76.95m | 71.90m | 68.00 | -- | 1.38 | -- | 11.99 | -18.70 | -18.70 | 1.12 | 14.53 | 0.0688 | -- | -- | 90,863.63 | -88.31 | -51.20 | -117.62 | -59.73 | -- | -- | -1,283.19 | -1,399.21 | -- | -- | 0.004 | -- | 11.66 | -- | 8.71 | -- | -62.36 | -- |
| VolitionRX Ltd | 1.29m | -29.87m | 73.12m | 110.00 | -- | -- | -- | 56.87 | -0.3623 | -0.3623 | 0.0155 | -0.2328 | 0.0837 | -- | 7.41 | 11,689.36 | -196.61 | -111.92 | -- | -196.20 | -- | -- | -2,348.71 | -10,793.31 | -- | -104.15 | -- | -- | 153.04 | -- | -16.68 | -- | 29.13 | -- |
| Adicet Bio Inc | 0.00 | -117.88m | 74.16m | 143.00 | -- | 0.3506 | -- | -- | -1.70 | -1.70 | 0.00 | 2.57 | 0.00 | -- | -- | 0.00 | -49.20 | -37.03 | -53.58 | -40.28 | -- | -- | -- | -748.46 | -- | -- | 0.00 | -- | -100.00 | -- | -104.41 | -- | 65.27 | -- |
| ALX Oncology Holdings Inc | 0.00 | -151.16m | 74.37m | 89.00 | -- | 0.5436 | -- | -- | -2.98 | -2.98 | 0.00 | 2.59 | 0.00 | -- | -- | 0.00 | -74.50 | -34.34 | -89.35 | -36.47 | -- | -- | -- | -7,238.76 | -- | -- | 0.0851 | -- | -- | -- | -30.23 | -- | 14.30 | -- |
| Ovid Therapeutics Inc | 631.56k | -32.50m | 74.52m | 25.00 | -- | 0.9773 | -- | 117.99 | -0.4598 | -0.4598 | 0.0089 | 1.07 | 0.0056 | -- | -- | 15,789.00 | -28.55 | -20.78 | -31.34 | -23.27 | -- | -- | -5,146.15 | -56.16 | -- | -- | 0.00 | -- | -73.93 | -- | 3.38 | -- | -17.14 | -- |
| Sellas Life Sciences Group Inc | 0.00 | -32.28m | 75.27m | 16.00 | -- | 4.74 | -- | -- | -0.7113 | -0.7113 | 0.00 | 0.2468 | 0.00 | -- | -- | 0.00 | -186.64 | -111.48 | -527.32 | -184.29 | -- | -- | -- | -1,289.42 | -- | -- | 0.00 | -- | -100.00 | -- | 9.59 | -- | -- | -- |
| Bioatla Inc | 11.00m | -81.82m | 75.90m | 65.00 | -- | 3.30 | -- | 6.90 | -1.70 | -1.70 | 0.2284 | 0.4751 | 0.103 | -- | -- | 169,230.80 | -76.61 | -48.72 | -103.22 | -57.35 | -- | -- | -743.79 | -6,651.71 | -- | -- | 0.00 | -- | -- | -- | -15.95 | -- | -37.01 | -- |
| P3 Health Partners Inc | 1.48bn | -102.69m | 76.19m | 400.00 | -- | 0.2863 | -- | 0.0516 | -0.753 | -0.753 | 11.08 | 0.744 | 1.71 | -- | 12.28 | 3,691,575.00 | -28.94 | -- | -83.29 | -- | -2.72 | 0.1781 | -16.95 | -56.93 | -- | -12.94 | 0.3358 | -- | 20.67 | 70.58 | 78.61 | -- | -11.20 | -- |
| Regencell Bioscience Holdings Ltd | 0.00 | -4.30m | 76.39m | 12.00 | -- | 9.29 | -- | -- | -0.3306 | -0.3306 | 0.00 | 0.6316 | 0.00 | -- | -- | 0.00 | -41.44 | -56.31 | -42.99 | -77.51 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 26.73 | -- | -- | -- |
| Aerovate Therapeutics Inc | 0.00 | -84.61m | 76.79m | 51.00 | -- | 0.954 | -- | -- | -2.99 | -2.99 | 0.00 | 2.79 | 0.00 | -- | -- | 0.00 | -72.99 | -- | -81.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -46.61 | -- | -- | -- |
| PDS Biotechnology Corp | 0.00 | -40.56m | 76.95m | 25.00 | -- | 3.50 | -- | -- | -1.17 | -1.17 | 0.00 | 0.5975 | 0.00 | -- | -- | 0.00 | -73.98 | -51.63 | -98.74 | -59.00 | -- | -- | -- | -- | -- | -19.13 | 0.5286 | -- | -- | -- | -5.11 | -- | -- | -- |
Data as of Nov 25 2024. Currency figures normalised to Aligos Therapeutics Inc's reporting currency: US Dollar USD
49.78%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 30 Sep 2024 | 315.10k | 10.26% |
| EcoR1 Capital, LLCas of 30 Sep 2024 | 255.57k | 8.32% |
| Deep Track Capital LPas of 30 Sep 2024 | 244.11k | 7.95% |
| Adage Capital Management LPas of 30 Sep 2024 | 218.81k | 7.12% |
| Altitude Crest Partners, Inc.as of 31 Mar 2024 | 113.79k | 3.70% |
| Woodline Partners LPas of 30 Sep 2024 | 91.97k | 2.99% |
| Baker Bros. Advisors LPas of 30 Sep 2024 | 83.06k | 2.70% |
| HHLR Advisors Ltd.as of 30 Sep 2024 | 76.25k | 2.48% |
| UBS O'Connor LLCas of 30 Sep 2024 | 67.10k | 2.18% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 63.81k | 2.08% |
More ▼
Data from 31 Mar 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
